Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -31.17% is in line with its 2-year average of -28.49%, around the middle of its 2-year range (-50.41%–-16.93%).
As of the fiscal period ended Tuesday, June 30, 2026. 24.29% below its 12-month average of -25.08%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -31.17%.
RETURN ON INVESTED CAPITAL (ROIC)
-31.17%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-25.08%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-24.29%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.61%
median of 610 covered companies
CURRENT VS SECTOR MEDIAN
+7.29%
vs the sector median at left
Beta Bionics, Inc.
Market Cap
$838.16M
Return on Invested Capital (ROIC)
-31.17%
TTM Avg
-25.08%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$830.70M
Return on Invested Capital (ROIC)
-94.76%
TTM Avg
-114.06%
3Y Avg
-144.57%
5Y Avg
-144.57%
Market Cap
$847.73M
Return on Invested Capital (ROIC)
-28.69%
TTM Avg
-21.44%
3Y Avg
-33.52%
5Y Avg
-49.04%
Market Cap
$821.00M
Return on Invested Capital (ROIC)
-37.39%
TTM Avg
-65.53%
3Y Avg
-61.64%
5Y Avg
-93.68%
Market Cap
$809.02M
Return on Invested Capital (ROIC)
-7.99%
TTM Avg
-8.85%
3Y Avg
-21.37%
5Y Avg
-42.56%
Market Cap
$807.90M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$870.53M
Return on Invested Capital (ROIC)
-25.25%
TTM Avg
-75.69%
3Y Avg
-67.13%
5Y Avg
-61.15%
Market Cap
$805.59M
Return on Invested Capital (ROIC)
9.20%
TTM Avg
13.08%
3Y Avg
19.17%
5Y Avg
23.78%
Market Cap
$887.93M
Return on Invested Capital (ROIC)
54.39%
TTM Avg
-47.91%
3Y Avg
-50.01%
5Y Avg
-47.22%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $838.16M | -31.17% | -25.08% | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $830.70M | -94.76% | -114.06% | -144.57% | -144.57% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $847.73M | -28.69% | -21.44% | -33.52% | -49.04% |
| Jade Biosciences, Inc. (JBIO)vs › | $821.00M | -37.39% | -65.53% | -61.64% | -93.68% |
| Ardelyx, Inc. (ARDX)vs › | $809.02M | -7.99% | -8.85% | -21.37% | -42.56% |
| Apnimed, Inc. (APMD)vs › | $807.90M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $870.53M | -25.25% | -75.69% | -67.13% | -61.15% |
| InMode Ltd. (INMD)vs › | $805.59M | 9.20% | 13.08% | 19.17% | 23.78% |
| Arbutus Biopharma Corp (ABUS)vs › | $887.93M | 54.39% | -47.91% | -50.01% | -47.22% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $785.44M | -9.77% | 8.57% | -11.39% | -51.99% |
ROIC
-31.2%
ROE
-28.5%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -31.17% |
| 2026-03-31 | -27.49% |
| 2025-12-31 | -24.07% |
| 2025-09-30 | -22.52% |
| 2025-06-30 | -20.14% |
| 2025-03-31 | -16.93% |
| 2024-12-31 | -35.22% |
| 2024-09-30 | -50.41% |
